Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of CPX-351 in Myeloid Leukemia in Children with Down Syndrome
2022-501457-37-00Phase 3Authorised
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3 trial of cytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Event-free survival. Planned start Aug 2023; status: authorised.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2022-501457-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501457-37-00.